Physician profile
David Bae
NPI 1053706325
$3,193.70
in general payments reported to CMS, 2019-2025
13 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $723 · 2023: $999 · 2024: $1,026 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,470.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,271.37 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $284.11 | 2023-2024 | Impella |
| Boston Scientific Corporation | $136.84 | 2024-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.28 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $83.28 | 2023-2025 | Wainua, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.37 | 2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $60.59 | 2022-2023 | |
| Medtronic, INC. | $55.40 | 2023 | Linq II |
| Ceribell, INC. | $47.58 | 2025 | Pocket Eeg Device |
| Alnylam Pharmaceuticals INC. | $35.27 | 2025 | Amvuttra |
| Daiichi Sankyo INC. | $23.69 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $17.65 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.27 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.